Is Stem Cell Therapy in Japan Safe? What to Know

Stem cell therapy in Japan operates within a specific legal safety framework: the Act on the Safety of Regenerative Medicine, which classifies treatments by risk level and requires provider review by a certified regenerative medicine committee before treatment begins. StemCellor organizes information and appointment coordination; the receiving licensed physician or medical institution confirms which regulatory category applies and whether a treatment can be appropriately offered for your case — safety here is a matter of regulated process, not a marketing claim.

The legal framework behind "safe"

Japan's Act on the Safety of Regenerative Medicine classifies regenerative treatments into three risk-based categories and requires each provider to submit a regenerative medicine provision plan for review by a certified regenerative medicine committee before treatment can begin. This framework exists to review a clinic's processes — screening, cell processing, and post-treatment monitoring — before treatment starts. It is a review of process, not a certification or guarantee of any individual patient's outcome. Our Safety & Regulation overview covers this framework, along with StemCellor's own current regulatory status, in full.

How cells are screened and processed

Before any tissue is collected, you undergo an infectious-disease blood screening, and your physician reviews your medical history for conditions that would make treatment inappropriate. Cells collected from your own tissue are then cultured and purified at a cell-processing facility under controlled, clean-room conditions over several weeks, and only cells confirmed sterile and genetically stable are released for use. We describe these processing conditions in general terms deliberately — we don't claim a specific third-party facility certification or a named partner facility unless that relationship has been independently confirmed.

What "safe" does not mean

A regulated framework and a careful process are not the same thing as a guaranteed outcome. No specific treatment result is guaranteed for any treatment on this site, and stem cell therapy does not cure a diagnosed disease or reverse the aging process — our protocols are intended to support the body's own regenerative and circulatory capacity. Some patients are advised not to proceed, or to delay treatment, as part of a genuine eligibility review described on our International Patient Guide, and that's an expected outcome of the process rather than a rare exception.

What the actual risks are

Minor risks are possible with any procedure involving tissue collection or injection — for example localized pain, swelling, bruising, or infection at the treatment site. Rare systemic reactions have been reported in the wider clinical literature on autologous stem cell infusion. Your physician reviews the risks relevant to your specific case during your eligibility review, before you consent to treatment, not after it has begun. Full treatment detail is on our Stem Cell Therapy page, and published pricing for this treatment, alongside its safety framework, is on our Pricing page.

Frequently asked questions

Does "Category II" mean this treatment is higher risk than other categories?

Category II sits in the middle of Japan's three-tier risk classification for regenerative medicine — it requires committee review before treatment begins, unlike lower-oversight categories, but is not the highest-risk tier in the system.

Does StemCellor have a confirmed regulatory plan number?

StemCellor does not itself hold or claim a regenerative medicine provision plan acceptance number on this site. Filings of this kind are associated with the treating medical institution, not with StemCellor as a coordination service; the receiving licensed physician or medical institution confirms the applicable regulatory category and filing status as part of your individual case review.

Is the cell-processing facility certified?

We describe our processing conditions as controlled, clean-room conditions. We don't claim a specific third-party facility certification or a named partner facility unless that relationship has been independently confirmed.

Can side effects be ruled out entirely?

No procedure involving tissue collection or injection is entirely without risk. Your physician reviews the risks relevant to your treatment with you before you consent.

Where can I read more about what StemCellor can and cannot promise?

Our FAQ page and Safety & Regulation overview both cover this directly.

References

Toyserkani NM, Jørgensen MG, Tabatabaeifar S, Jensen CH, Sheikh SP, Sørensen JA. "Concise Review: A Safety Assessment of Adipose-Derived Cell Therapy in Clinical Trials: A Systematic Review of Reported Adverse Events." Stem Cells Translational Medicine. 2017;6(9):1786-1794. DOI: 10.1002/sctm.17-0031